August 24, 2016 07:50 AM EDT
R&D

Still in spot­light of a fed­er­al probe, In­sys touts PhI­II pain study as it preps an NDA

John Carroll

Editor & Founder

Still in the spot­light for fed­er­al in­ves­ti­ga­tions sur­round­ing sev­er­al cas­es of off-la­bel mar­ket­ing, In­sys Ther­a­peu­tics $IN­SY says it has come up with promis­ing Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times